Aims-To investigate the level of matrix metalloproteinase activity during the time-course of cartilage explant proteoglycan breakdown; to determine the effects of selective small-molecule inhibitors of matrix metalloproteinases on proteoglycan degradation. Methods-The levels of matrix metalloproteinase activity in cartilage explant cultures and conditioned media were monitored by use of a quenched fluorescent substrate. The constants for inhibition of certain matrix metalloproteinases by a series of synthetic inhibitors were determined. Bovine and human cartilage explant cultures were treated with interleukin-1, tumour necrosis factor or retinoic acid and the amount ofproteoglycan released into the culture medium in the absence and presence of the inhibitors was quantified. Control experiments, examining the inhibition of other proteinases, and investigating possible toxic or non-specific effects of the inhibitors, were carried out. Results-The profile of inhibition of proteoglycan release suggested the involvement of interstitial collagenase-like, rather than gelatinase-or possibly stromelysin-like, proteinases. No evidence was found for toxic or non-specific mechanisms of inhibition. Very low levels of activity of the known matrix metalloproteinases were present during the timecourse of aggrecan breakdown. Conclusions-A novel collagenase-like proteinase(s) may be involved in cartilage proteoglycan breakdown. Gelatinase-type matrix metalloproteinases do not seem to be involved in this process. Specific collagenase inhibitors may be therapeutically efficacious in the treatment of arthritis.
Aims-To investigate the level of matrix metalloproteinase activity during the time-course of cartilage explant proteoglycan breakdown; to determine the effects of selective small-molecule inhibitors of matrix metalloproteinases on proteoglycan degradation. Methods-The levels of matrix metalloproteinase activity in cartilage explant cultures and conditioned media were monitored by use of a quenched fluorescent substrate. The constants for inhibition of certain matrix metalloproteinases by a series of synthetic inhibitors were determined. Bovine and human cartilage explant cultures were treated with interleukin-1, tumour necrosis factor or retinoic acid and the amount ofproteoglycan released into the culture medium in the absence and presence of the inhibitors was quantified. Control experiments, examining the inhibition of other proteinases, and investigating possible toxic or non-specific effects of the inhibitors, were carried out. Results-The profile of inhibition of proteoglycan release suggested the involvement of interstitial collagenase-like, rather than gelatinase-or possibly stromelysin-like, proteinases. No evidence was found for toxic or non-specific mechanisms of inhibition. Very low levels of activity of the known matrix metalloproteinases were present during the timecourse of aggrecan breakdown. Conclusions-A novel collagenase-like proteinase(s) may be involved in cartilage proteoglycan breakdown. Gelatinase-type matrix metalloproteinases do not seem to be involved in this process. Specific collagenase inhibitors may be therapeutically efficacious in the treatment of arthritis. Aggregating proteoglycan (aggrecan) and type II collagen are the major extracellular protein components of cartilage. Loss of proteoglycan and its associated water can compromise the structure and function ofcartilage by reducing its resilience to compressive loading and increasing friction during joint motion.' 2Thus, depletion of articular cartilage proteoglycan (seen on x ray film as joint space narrowing) may predispose the cartilage to further mechanical damage. Preventing pathological cartilage proteoglycan breakdown may therefore substantially protect the affected joint and help prevent the development of an arthritic lesion. The mechanism by which cartilage proteoglycan is degraded is not fully understood, although recent evidence would suggest the involvement of a number of proteolytic enzymes in a cascade reaction that may result in the activation of an as yet undiscovered enzyme, "aggrecanase" (reviewed elsewhere3).
There is evidence that members of the matrix metalloproteinase (MMP), or Matrilysin and stromelysin 1 activities were measured in assays using '4C-casein as the substrate.30 Gelatinase A and B activities were assayed by a modification of the previously described procedure,3' with the addition of 50 gg/ml gelatin. IC50 values were found by comparing enzyme activity in the presence of varying concentrations of the inhibitors, and fitting a curve to the data thus obtained. The inhibitor concentration that gave 50% inhibition was then acquired by interpolation.
CARTILAGE CULTURES
Most of the work reported here has been done on normal bovine cartilage, which has been shown previously to behave catabolically in a manner similar to the human tissue.3 However, a limited number of experiments were done using two samples of non-arthritic human cartilage. One sample was from the femoral condyle of an 81 year old man with no history of arthritic disease. The second sample was from the interphalangeal joint of the left big toe of a 14 year old boy who underwent fusion of the joint in response to a non-arthritic foot deformity. Cartilage was sliced, to give an explant size of approximately 3 x 3 x 2 mm. The slices were pre-incubated in MEM containing 10% (v/v) FCS, penicillin (100 u/ml) and streptomycin (100 jg/ml) for two days.
They were then transferred individually to wells of a 96-well plate containing 195 jl MEM containing 1% (v/v) FCS to which the inhibitors were added from 100-fold concentrated stock solutions in methanol. After one hour Ret was added to a final concentration of 1 gM. The cultures were maintained for five days after which the media and explants were stored frozen pending analysis.
Bovine nasal septum cartilage explants were prepared and preincubated as described previously.32 The cartilage discs were transferred individually to wells of a 96-well plate, with 195 gl of serum-free DMEM to which the metalloproteinase inhibitors were added from 100-fold stock solutions in methanol. A 1% (v/v) concentration of methanol did not affect cartilage catabolism (data not shown). After one hour, rhIL-la, rhTNFx, or Ret was added to final concentrations of 250 U (0.3 nM), 5000 U (3.5 nM), or 10-6 M, respectively. The cultures were maintained for up to five days with a medium change after two days, the fresh medium containing exactly the same constituents as the original. Conditioned media and discs were stored frozen pending analysis. In studies examining the effects of the MMP inhibitors on stimulated proteoglycan release from all types of cartilage examined, only experiments in which the addition of the stimulus resulted in at least a doubling of the amount of proteoglycan release were included in the analyses. This helped to ensure that the detected inhibition was of stimulated, as well as basal, release.
Bovine articular cartilage slices were dissected from metacarpophalangeal joints and preincubated as reported previously,'5 after which the explants were treated as described earlier for the nasal cartilage discs. As shown elsewhere'5 articular cartilage was less responsive than nasal cartilage to the presence of human cytokines. The concentrations of rhIL-1 ex and rhTNFax were therefore increased to 1800 U (2 nM) and 10 000 U (7 nM), respectively. The cultures were maintained for five days with a medium change on day 2, after which the media and cartilage pieces were stored frozen.
DETERMINATION OF PROTEOGLYCAN DEGRADATION
The amount of proteoglycan in the culture medium was determined as sulfated glycosaminoglycan by use of dimethylmethylene A small number of experiments were carried out to investigate the inhibitory effects of BB87 and BB250 on human articular cartilage proteoglycan breakdown. As described in the Methods section, we obtained two samples of non-arthritic cartilage. Both of these responded catabolically to the presence of 1 ,uM Ret, releasing about 40% of total glycosaminoglycan by day 5 in the presence of the vitamin, and about 10% in its absence. BB250 and BB87 at a dose of 10 jiM both strongly inhibited the release of proteoglycan from human cartilage. In one sample, basal levels of release were inhibited by (mean (SEM)) 32% (12%) (p < 0.001) by BB250 and 41% (6%) (p < 0.0001) by BB87. Inhibition of Ret stimulated release was even more notable, the two inhibitors giving 93% (5%) (p < 0.001) and 99% (4%) (p < 0.001), respectively. In a second experiment with cartilage from a different patient, BB250 at a concentration of 10 jiM produced 38% (16%) (NS) inhibition of basal release and 102% (5%) (p < 0.001) inhibition of Ret stimulated proteoglycan release.
The effects of rhIL-lat and BB87 on bovine nasal cartilage explants were assessed histologically, by use of toluidine blue, which binds to sulfated glycosaminoglycans. Cartilage cultured for 24 hours in the absence of catabolic stimulus retained most of its metachromasia and hence its proteoglycan content (fig IA) , the sections staining darker in the territorial than in the interterritorial matrix. This was also the case with cartilage taken from freshly slaughtered cattle and processed for histology without the culture period (not shown). Explants cultured in the presence of rhIL-1 x for 24 hours stained less intensely (fig 1 B) . The presence of BB250 in rhIL-lx treated 24 hour cultures was chondroprotective, the histological appearance (fig 1 C) being very similar to that of the unstimulated controls ( fig 1A) .
EFFECTS OF BB87 AND BB250 ON THE METABOLIC ACTIVITY OF NASAL SEPTUM CARTILAGE EXPLANTS
Proteoglycan release from cartilage explants can be inhibited non-specifically by toxic compounds such as iodoacetate. 32 We therefore evaluated the effects of the inhibitory compounds on some metabolic activities of chondrocytes, and determined whether the inhibitory effect on proteoglycan degradation was reversible.
The ability of nasal cartilage explants to recover from the effects of BB87 and BB250 was investigated. The explants were cultured for two days with rhIL-1la (0.3 nM) and either of the inhibitors (10 gM) after which the explants were allowed to recover in cytokinefree DMEM for 24 BB87 and BB250 were also tested for their effects on protein synthesis, as assessed by incorporation of 35S-methionine into material that was insoluble in trichloroacetic acid.
BB250 had no effect on 35S-methionine incorporation, either in the presence or absence of rhIL-lac. BB87 slightly decreased 35S-methionine incorporation (19.7% at a concentration of 10 gM) in the absence of IL-1, but had no effect in its presence.
It is possible that proteinase inhibitors affect signal transduction pathways and subsequent gene expression rather than the activities of proteolytic enzymes involved specifically in the breakdown of cartilage proteoglycan. IL-1, TNF and Ret inhibit the synthesis of cartilage proteoglycan by chondrocytes.374' 34 We therefore examined the effect of BB87 on rates of proteoglycan synthesis by nasal cartilage discs in the presence of rhIL-ia, in the knowledge that interference with signal transduction pathways by the inhibitor would be manifested by an increase in the rate of synthesis when compared with the effect of the cytokine on its own. The MMP inhibitor at a concentration of 10 pM did not seem to have any effect on rates of proteoglycan synthesis. The control level of incorporation of 7900 (700) (mean (SEM)) counts per minute (cpm)/disc was not significantly altered by the presence of BB87 (7200 (700) cpmldisc). As expected, rhIL-lIx significantly depressed 35SO4 incorporation, to 3000 (200) cpmldisc (p < 0.0001). Again, this value was not significantly changed by the presence of BB87 (2900 (200) cpmldisc).
We conclude from these studies on the metabolic activity of cartilage explants that the inhibitory action of the MMP inhibitors on proteoglycan breakdown is likely to be due to a specific inhibition of the activity of a metalloproteinase, rather than to any toxic or nonspecific effect of the compounds.
LEVELS OF MMP ACTIVITY DURING THE TIME-COURSE OF PROTEOGLYCAN BREAKDOWN
As described in the Methods section, we used a quenched fluorescent substrate that is cleaved by all the MMPs to monitor the appearance of MMP activity during the time-course of proteoglycan breakdown in bovine nasal septum cartilage cultures. Very low levels of activity were found in media conditioned by the explants, even after five days of culture, irrespective of whether the explants were cultured in the presence or absence of agents that stimulate proteoglycan breakdown ( Explants were cultured in serum-free DMEM with or without a catabolic stimulant for up to five days with one medium change on day 2. The conditioned media were assayed for Mca-Pro-LeuGly-Leu-Dpa-Ala-Arg-NH2-hydrolysing activity in continuous rate assays as described in Methods. The results are expressed as pmol/min of product per explant. more activity was present following treatment with APMA, suggesting the presence of low amounts of proMMPs. The low levels of activity generated during the time-course of proteoglycan breakdown (< 0.6 pmol/min substrate hydrolysed/explant, without APMA treatment) can be contrasted with the level of over 15 000 pmol/min/explant found in week 3 medium from explants cultured in the presence of IL-lia, when collagen breakdown is occurring.45 There is thus a difference in MMP activity of over four orders of magnitude, between the times of proteoglycan and collagen breakdown.
It is possible that the bulk of MMP activity in our cultures remained associated with the explants rather than being secreted into the surrounding medium. It has been reported that active stromelysin 146 and other MMPs bind to components of the extracellular matrix, and indeed the enzymes can be extracted from solid tissues. 47 In order to examine this possibility we determined the levels of MMP activity in the cultures themselves, as opposed to the activity present in isolated conditioned media (earlier). Once again, the levels of active enzyme were very small, and there were no differences in the amounts of activity detected in cultures with and without rhIL-1 a, or any increase of enzyme activity with time ( systems."'-"' Our findings also suggest that at least one metalloproteinase may be involved irrespective of the catabolic stimulus to cartilage breakdown (the cytokines IL-1 and TNF, or the vitamin Ret) in both bovine and human systems. As far as we are aware, this study is the first to investigate the effect of MMP inhibitors on TNF stimulated breakdown and the first to demonstrate inhibition of proteoglycan release from human cartilage by MMP inhibitors.
Our results clearly show the lack of inhibition of stimulated proteoglycan breakdown by compounds, BB2001, BB2014 and BB3003, that show a considerable degree of selectivity for the inhibition of gelatinase activity. It therefore seems unlikely that gelatinase(s) is involved in proteoglycan breakdown stimulated by IL-1, TNF or Ret in our model systems.
We found that inhibitors of collagenase-type MMPs were effective at inhibiting cartilage proteoglycan breakdown, implicating the activity of a collagenase-like MMP in proteoglycan loss. We must interpret this result with some caution, because inhibitor concentrations well in excess of the IC50 values determined in in vitro experiments must be used to obtain inhibition of proteoglycan breakdown in tissue systems. An example of this phenomenon was our earlier work with BB94,'5 an inhibitor with low nanomolar inhibition constants with all the MMPs tested so far. Even so, in terms of the inhibition of proteoglycan breakdown, concentrations of about 0.1 ,uM were required to effect 50% inhibition. The reasons for this apparent discrepancy are not yet clear, but may be related to problems of accessibility to the target enzyme in cartilage, competition between the inhibitor and very high concentrations of substrate within cartilage or, alternatively, may suggest that the physiologically important enzyme has yet to be identified. Our finding that very low levels of activity of the known MMPs were present in cultures during the time-course of proteoglycan breakdown strengthens the latter possibility. It procollagenase.50 However our data might argue against a role for stromelysin 1 in that BB87, a potent inhibitor of cartilage proteoglycan breakdown (table 2) , is a 20-fold tighter binding inhibitor of interstitial collagenase than it is of stromelysin 1 (table 1) . Although a recent independent study5" has also provided evidence against a role for stromelysin in chondrocyte mediated proteoglycan breakdown, confirmation will await the results of experiments using probes that are more selective for stromelysins.
The loss of aggrecan from human cartilage, both in various disease states and in tissue culture models, predominantly occurs coincident with a specific proteolytic cleavage produced by the action of an as yet unidentified proteinase referred to as "aggrecanase", at a Glu-Ala bond within the interglobular region towards the N-terminus of aggrecan. This results in the loss from the matrix of almost the complete aggrecan molecule."5 52-55 The Glu-Ala bond is not cleaved in vitro by any known MMP other than neutrophil collagenase (EC 3.4.24.34),56 perhaps suggesting that neutrophil collagenase is "aggrecanase" (reviewed elsewhere3). Although data presented here, and the fact that neutrophil collagenase has been identified recently in chondrocytes,57 would seem to support this hypothesis, there are observations that lend credence to the view that the enzyme responsible for aggrecan cleavage is not neutrophil collagenase. Neutrophil collagenase cleaves another bond in the interglobular region of aggrecan, a Asn-Phe bond that is the favoured cleavage site of most MMPs,58-60 more efficiently than it cleaves the Glu-Ala bond. 56 Although the product of cleavage of the Asn-Phe bond can be found in human cartilage,6' the available evidence suggests that this is only a minor product and that cleavage at the Glu-Ala bond prevails in the human arthritic diseases54 and in cartilage culture systems. 55 Similarly, there is evidence that interstitial collagenase and collagenase-3 are not responsible for aggrecan breakdown. Although interstitial collagenase is capable of slowly cleaving aggrecan in the test tube,62 and cleaves the interglobular region at two distinct sites,59 neither of these correspond to the "aggrecanase" cleavage site. Most importantly we have demonstrated that virtually no active collagenase is produced by bovine cartilage explants during the first week of culture.45 It is also worth noting that the natural protein inhibitor of the MMPs, Timpi, does not inhibit cartilage explant proteoglycan release. '6 This observation, together with the very low levels of MMP activity present in our cultures, virtually precludes a role for any of the known MMPs in aggrecan degradation. Our results do indicate, however, that a collagenase-like metalloproteinase may be important in aggrecan breakdown, and the previous demonstration of "aggrecanase"-like activity by neutrophil collagenase56 may suggest that "aggrecanase" is a metalloproteinase with some active site features similar to those of the neutrophil enzyme.
The cascade nature of the events leading up to aggrecan breakdown3 unfortunately do not allow us to discriminate between the inhibition of an enzyme acting directly on aggrecan as opposed to an enzyme involved in "proaggrecanase" activation. The involvement of members of the gelatinase group of MMPs in the events leading to aggrecan breakdown in our model system does now seem unlikely, however.
In any event, the demonstration of potent inhibition of chondrocyte mediated aggrecan breakdown by inhibitors of collagenase-like MMPs may provide a lead for the development of selective inhibitors as therapeutic agents for the treatment of arthritic diseases. The same inhibitors also inhibit type II collagen breakdown in cartilage explants45 and discriminating inhibitors are less likely to produce unwanted side effects than those with a broader inhibition profile.
